Supplementary Material for "Effectiveness of Paxlovid - a review" by

Sydney Paltra^{1,*}, Tim Conrad²

Supplementary Material

The following section contains three tables: The first table contains the preprints and papers, which met the inclusion criteria and were considered in our review. The second table contains the preprints and papers, which were included in our study, but not the review itself and the final table includes all papers and preprints, whose title and abstracts were scanned, but which did not meet the inclusion criteria.

Used

Author(s)	Title	Type of publication & journal
(Arbel <i>et al.</i> , 2022)	Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron Surge	Preprint
(Dryden-Peterson <i>et al.</i> , 2022)	Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system	Preprint
(Ganatra et al., 2022)	Oral Nirmatrelvir and Ritonavir in Non-hospitalized Vaccinated Patients with Covid-19	Published in <i>Clinical Infectious Diseases</i>
(Hammond <i>et al.</i> , 2022)	Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19	Published in New England Journal of Medicine
(Najjar-Debbiny <i>et al.</i> , 2022)	Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients	Published in <i>Clinical Infectious Diseases</i>

¹ Transport Systems Planning and Transport Telematics, TU Berlin Sekr. KAI 4-1, Kaiserin-Augusta-Allee 104, 10553 Berlin, Germany

² Zuse Institute Berlin, Takustraße 7, 14195 Berlin, Germany

^{*} Corresponding author; paltra@tu-berlin.de, +493031470951

Kong's Omicron BA.2 wave: an observational study

Table S1: Publications which were considered in our review.

Used, but not in review

Author(s)	Summary	Used in section
(Epling <i>et al.</i> , 2022)	Examination (clinically, virologically and immunologically) of seven patients who experienced rebound symptoms. Six experienced rebound symptoms after taking Paxlovid, the final patient did not receive the treatment.	Discussion
(Extance, 2022)	Short sections on who is eligible for treatment with Paxlovid, how does Paxlovid work, what peer reviewed evidence is there for Paxlovid, which countries are using Paxlovid, how much does Paxlovid cost, what is the potential for this drug.	Paxlovid (Ritonavir and Nirmatrelvir)
(Fishbane, Hirsch and Nair, 2022)	Argue that Paxlovid might harm transplant patients as there is a chance of medication interaction and that the ritonavir component of paxlovid might pose a safety risk for these patients	Discussion
(L. Wang, Volkow, <i>et al.</i> , 2022)	Discussion of if and how rebound symptoms after taking Paxlovid differ between Omicron BA.5 and	Discussion

Author(s)	Summary	Used in section
	Omicron BA.2.12.1 infected patients	
(Marzolini <i>et al.</i> , 2022)	Review which summarized the effects of ritonavir on drug disposition and debates what influences the probability of drug-drug interaction when taking Paxlovid.	Discussion
(Prikis and Cameron, 2022)	Discusses side-effects of Paxlovid in a single kidney transplant patient, whos treatment with Paxlovid had to be interrupted and who suffered acute kidney injury from taking the drug	Discussion
(Rubin, 2022)	No abstract available on Pubmed, published under "Medical News & Perspectives", discussing rebound effects potentially associated with Paxlovid treatment.	Discussion
(Vangeel et al., 2022)	Assessment of the in vitro antiviral effect of GS-441524, remdesivir, EIDD-1931, molnupiravir and nirmatrelvir against the various SARS- CoV-2 VOCs, including Omicron.	Discussion
(Wen <i>et al.</i> , 2022)	Review of efficacy and safety of the three antiviral treatments molnupiravir, fluvoxamine and Paxlovid. Published, when only Paxlovid's clinical results were available.	Introduction

Table S2: Publications which were considered in our paper, but not in the review itself.

Unused Table

Author(s)	Summary	Reason for Exclusion
(Abdelrahim et al., 2022)	Discussing Thymoquinone and other natural products as possible treatments for COVID-19.	Does not meet the inclusion criteria.
(Alshanqeeti and Bhargava, 2022)	Case discussion of two patients who were prescribed Paxlovid and experiences a rebound of COVID-19	Does not meet the inclusion criteria.
(Alvarado et al., 2022)	Paxlovid binds non-covalently at regions other than the catalytic sites with energies stronger than reported, namely to mMpro.	Does not meet the inclusion criteria.
(Ashour <i>et al.</i> , 2022)	Review which presents the efficacy of repurposed drugs for COVID-19. Discussion of clinical trials, combination therapies and novel methods followed for treatment. Written when Paxlovid was undergoing Phase III studies.	Does not meet the inclusion criteria.
(Atluri, Aimlin and Arora, 2022)	Debating evidence from pivotal trials that led to the approval of effective COVID-19 therapeutics and categorizing them as effective outpatient and inpatient management strategies.	Does not meet the inclusion criteria.
(Azanza <i>et al.</i> , 2022)	Description of drugs that contraindicated and/or should (not) be used carefully when also taking Paxlovid based on fact sheets by the Spanish Agency for Medicines and Health Products.	Does not meet the inclusion criteria.
(Bartha <i>et al.</i> , 2022)	Proposition of a hybrid multiscale mathematical approach to assess Paxlovid.	Does not meet the inclusion criteria.
(Ben Hlima <i>et al.</i> , 2022)	Usage of techniques of structure modeling, in silico	Does not meet the inclusion criteria.

Author(s)	Summary	Reason for Exclusion
	docking and pharmacokinetics prediction to test compounds from algae for their ability to inhibit SARS-CoV-2's protease Mpro.	
(Berar Yanay et al., 2022)	No abstract available on pubmed.	
(Birabaharan and Martin, 2022)	Discussion of the case of a male veteran reporting rebound symptoms after Paxlovid treatment. The patient was found to be hypoxic with pulmonary emboli.	Does not meet the inclusion criteria.
(Borio, Bright and Emanuel, 2022)	No abstract available on pubmed.	Abstract unavailable.
(Brooks, Song and Sultan, 2022)	No abstract available on pubmed.	Abstract unavailable.
(Burki, 2022)	No abstract available on pubmed.	Abstract unavailable.
(Buxeraud, Faure and Fougere, 2022)	The English abstract solely states that Paxlovid is an available treatment for COVID-19 infections, administered orally and to people at high risk for severe disease.	Only the abstract was available in English.
(Callaway, 2022)	No abstract available on pubmed.	Abstract unavailable.
(Catlin <i>et al.</i> , 2022)	Written when Paxlovid was still under development, embryo-fetal development studies in rats and rabbits to assess clinically relevant risks when prescribing Paxlovid to males and females in reproductive age.	Does not meet the inclusion criteria.
(Cerón-Carrasco, 2022)	Aim to critically assess benefits and shortcomings of using molecular models for drug repurposing when trying to develop effective	Does not meet the inclusion criteria.

Author(s)	Summary	Reason for Exclusion
	COVID-19 treatments	
(Chen, Chang and Wei, 2022)	No abstract available on pubmed.	Abstract unavailable.
(Choi <i>et al.</i> , 2022)	Discussing panax ginseng's (a medical plant) ability to control cytokine storm in COVID-19	Does not meet the inclusion criteria.
(Collaborative et al., 2022)	Identification of patients potentially eligible for treatment with Paxlovid in the UK. In consequence, assessment of the coverage of new treatments among these patients with the conclusion that there were variants in coverage between key clinical, geographic and demographic groups.	Does not meet the inclusion criteria.
(Coulson et al., 2022)	No abstract available on pubmed.	Abstract unavailable.
(Couzin-Frankel, 2021)	No abstract available on pubmed.	Abstract unavailable.
(Dai <i>et al.</i> , 2022)	For 36 mRNA-vaccinated and Omicron-infected individuals viral kinetics were measured. 11 of the 36 were treated with Paxlovid and treatment was associated with larger incidence of viral rebound.	Does not meet the inclusion criteria.
(de Oliveira et al., 2022)	Report of simulation of H172Y mutation on Mpro's structure leading to decreased structural stability and binding affinity.	Does not meet the inclusion criteria.
(Deo et al., 2022)	Evaluation of the incidence of viral and symptom rebound in untreated mild to moderate COVID-19 outpatients.	Does not meet the inclusion criteria.
(Drożdżal <i>et al.</i> , 2021)	Review presenting the progress in clinical trials concerning the effectiveness	Does not meet the inclusion criteria.

Author(s)	Summary	Reason for Exclusion
	of treatments for COVID-19. Written when solely the results from Paxlovid's clinical trials were available.	
(Rubin, Baden and Morrissey, 2022)	No abstract available on pubmed.	Abstract unavailable.
(Eng et al., 2022)	Presenting the preclinical disposition, metabolism and potential drug-drug interaction of nirmatrelvir.	Does not meet the inclusion criteria.
(Feingold, 2022)	Discussion of levels of total cholesterol, LDL-C, HDL-C, and apolipoprotein B and A-I levels in patients with COVID-19 infections.	Does not meet the inclusion criteria.
(Feng <i>et al.</i> , 2022)	Discussing the potential of Yindan Jiedu granules as a treatment for COVID-19. Comparison of Yindan Jiedu granules and Paxlovid when treating COVID-19 patients.	Does not meet the inclusion criteria.
(Fernando <i>et al.</i> , 2022)	Present how Pfizer has successfully improved its research and development (R&D) productivity between 2010 and 2020.	Does not meet the inclusion criteria.
(Ferrara et al., 2022)	Presentation of literature on monotherapy use of Paxlovid and monotherapy use of remdesivir and discussion of the hypothesis of using nirmatrelvir and remdesivir to increase efficacy of COVID-19 treatment.	Does not meet the inclusion criteria.
(Gandhi, Malani and Del Rio, 2022)	No abstract available on pubmed.	Abstract unavailable.
(García-Lledó <i>et al.</i> , 2022)	Provides a review of currently available COVID-19 treatments. As this was published in December 2021, it only include the clinical trials for Paxlovid.	Does not meet the inclusion criteria.

Author(s)	Summary	Reason for Exclusion
(Gold <i>et al.</i> , 2022)	Data from December 2021 until May 2022 were analyzed to describe oral antiviral treatment prescription dispensing overall and by week, stratified by zip code and social vulnerability.	Does not meet the inclusion criteria.
(Greasley et al., 2022)	Evaluation of in vitro potency of normatrelvir against the Mpro of currently circulating (and previous) variants of concern. Their in vitro data suggests that Paxlovid has the ability to inhibit SARS-CoV-2 replication, even vor VOCs like Omicron.	Does not meet the inclusion criteria.
(Halford, 2022)	No abstract available on pubmed.	Abstract unavailable.
(Ho <i>et al.</i> , 2022)	Retrospective analysis of benefits and limitations of (previous) treatments for COVID-19. Calls Paxlovid a promising treatment, but only presents clinical results.	Does not meet the inclusion criteria.
(Hong <i>et al.</i> , 2022)	People with cystic fibrosis (CF) are at risk for drug-drug interaction when being treated with Paxlovid. Simulation of coadministration of elexacaftor-tezacaftor-ivacaf tor and Paxlovid to examine these potential interactions.	Does not meet the inclusion criteria.
(Huang <i>et al.</i> , 2022)	Case report of a severe aplastic anemia child who was successfully treated with Paxlovid.	Does not meet the inclusion criteria.
(Hung <i>et al.</i> , 2022)	Written before Paxlovid was authorized and before clinical results were available. Hence, discussing the promising antiviral effect of nirmateelvir, while also	Does not meet the inclusion criteria.

Author(s)	Summary	Reason for Exclusion
	naming (then) unresolved concerns.	
(Islam <i>et al.</i> , 2022)	Evaluation of drugs authorized in the US for treating COVID-19. For Paxlovid's effectiveness, solely the clinical results are discussed.	Does not meet the inclusion criteria.
(Javaux and Ader, 2022)	Discussing medical management (but excluding intensive care management) of COVID-19.	Article only available in French.
(Joyce, Hu and Wang, 2022)	Review to present the potential of nirmatrelvir when treating COVID-19, discussing its history of rational design, its target selectivity, synthesis and drug resistance.	Does not meet the inclusion criteria.
(Katella, 2022)	News article introducing the most important Paxlovid-related information for the general public and patients.	Does not meet the inclusion criteria.
(Kozlov, 2022)	No abstract available on pubmed.	Abstract unavailable.
(Kuehn, 2022)	No abstract available on pubmed.	Abstract unavailable.
(L. Wang, Berger, <i>et al.</i> , 2022)	Examination of rates and relative risks of COVID-19 rebound in patients treated with Molnupiravir or Paxlovid during January-June 2022	Does not meet the inclusion criteria.
(Lamb, 2022)	Summary of the milestones during the development of normatrelvir plus ritonavir leading to its first authorizations and approval for the treatment of COVID-19	
(Ledford and Maxmen, 2022)	No abstract available on pubmed.	Abstract unavailable.

Author(s)	Summary	Reason for Exclusion
(Ledford, 2022)	No abstract available on pubmed.	Abstract unavailable.
(Lee <i>et al.</i> , 2022)	Discussion of potential nirmatrelvir escape mutations from emerging variants of SARS-CoV-2 and exploration of the mutational landscape of Mpro.	Does not meet the inclusion criteria.
(Lemaitre, Budde, <i>et al.</i> , 2022)	Discussion of drug interactions of Paxlovid and immunosuppressant drugs and provision of general recommendations for therapeutic drug monitoring when co-administering the two.	Does not meet the inclusion criteria.
(Lemaitre, Grégoire, <i>et al.</i> , 2022)	Providing recommendations on behalf of the national French society of pharmacology for possible drug-drug interactions between Paxlovid and other commonly used drugs.	Does not meet the inclusion criteria.
(Li <i>et al.</i> , 2022)	No abstract available on pubmed.	Abstract unavailable.
(Lieber and Plemper, 2022)	Introduction of a potential future treatment, the orally available ribonucleoside analog 4'-fluorouridine (4'-FIU). Furthermore, reviewing currently approved and emerging medicines against COVID-19.	Does not meet the inclusion criteria.
(Chengyu Liu et al., 2022)	Discussing statin use in the context of COVID-19, coming to no evidence suggesting interference between statins and COVID-19 vaccines. But, simultaneous stantis and Paxlovid administration may increase statin exposure and the risk of adverse effects.	Does not meet the inclusion criteria.

Author(s)	Summary	Reason for Exclusion
(Chenxi Liu et al., 2022)	Development of an efficient LC-MS/MS method for simultaneously determining nirmatrelvir and ritonavir in human plasma.	Does not meet the inclusion criteria.
(Logue <i>et al.</i> , 2022)	Show that Apilimod and other PIKfyve inhibitors worsen disease in a COVID-19 murine model when given prophylactically or therapeutically. Abstract solely mentions Paxlovid as an available treatment.	Does not meet the inclusion criteria.
(Lu <i>et al.</i> , 2022)	Multicentre cohort study describing clinical characteristics, and assessing risk and protective factors for geriatric Omicron severe infections.	
(Mahaboob Ali <i>et al.</i> , 2022)	Discussing herbal extracts as potential treatments for COVID-19. Solely mentions that molnupiravir and Paxlovid are not widely available.	Does not meet the inclusion criteria.
(Mahase, 2021)	News article in BMJ, published shortly after the analysis of the phase II-III data was published. Hence, discussing and reporting the results of this analysis.	Does not meet the inclusion criteria.
(Malden <i>et al.</i> , 2022)	Consideration of electronic health record from a large integrated health care system in California to analyze and quantify hospital admissions and emergency department encounters related to COVID-19 during the 5-15 days after receiving Paxlovid treatment	Does not meet the inclusion criteria.
(Manus, 2022)	No abstract available, article in French.	

Author(s)	Summary	Reason for Exclusion
(Marzi <i>et al.</i> , 2022)	Report the discovery and description of nirmatrelvir. Comparison of effectiveness of molnupiravir and normatrelvir). Written while Paxlovid was under study in phase III of the clinical trial.	Does not meet the inclusion criteria.
(McDonald and Lee, 2022b)	Praxis-relevant recommendations for the usage and prescription of Paxlobid.	Does not meet the inclusion criteria.
(McDonald and Lee, 2022a)	No abstract available on pubmed.	
(McMillan, Morris and Idris, 2022)	News article published in EMBO Molecular Medicine, discussing (Chang et al., 2022)	Does not meet the inclusion criteria.
(Mikus <i>et al.</i> , 2022)	Compilation of a list of drugs and their potentially relevant interactions when being administered simultaneously with Paxlovid as well as a list of commonly prescribed drugs for which no such interactions exist.	Does not meet the inclusion criteria.
(Moghadasi <i>et al.</i> , 2022)	Discussion of how ongoing virus evolution has the potential to yield variants with resistance to clinical protease inhibitors (like Paxlovid).	Does not meet the inclusion criteria.
(Mohapatra et al., 2022)	Published when solely Paxlovid's clinical results were available. Hence, only these are discussed.	Does not meet the inclusion criteria.
(Mótyán <i>et al.</i> , 2022)	Review of normatrelvir's binding to SARS-CoV-2's Mpro and its potential inefficacy when novel mutations arise.	Does not meet the inclusion criteria.
(Ng <i>et al.</i> , 2022)	Presentation of current antiviral drugs for COVID-19 as well as potential future directions.	Does not meet the inclusion criteria.

Author(s)	Summary	Reason for Exclusion
(Nocentini, Capasso and Supuran, 2022)	Review of literature on the drug design landscape of SARS-CoV-2 Mpro inhibitors. Mentions nirmatrelvir as one such inhibitor.	Does not meet the inclusion criteria.
(Ou <i>et al.</i> , 2022)	Development of a non-pathogenic system in which yeast growth is a proxy for Mpro activity. Consequently, mutants which exhibit drug sensitivity and altered enzymatic activity can quickly be identified.	Does not meet the inclusion criteria
(Ouyang <i>et al.</i> , 2022)	Discussion of review of risk factors for severe covid and Pre-exposure prophylaxis (PrEP) strategies against SARS-CoV-2. Additionally, presentation of potential SARS-CoV-2 PrEP drugs	Does not meet the inclusion criteria.
(Parums, 2022)	Published in late 2021, reporting the current status of oral treatments for COVID-19	Does not meet the inclusion criteria.
(Pavan <i>et al.</i> , 2022a)	Analysis of newly reported bat coronaviruses with regard to the similarities and differences between their 3CL protease and SARS-CoV-2.	Does not meet the inclusion criteria
(Pavan <i>et al.</i> , 2022b)	Analysis of the structural features of the Spike protein and the Mpro of the SARS-CoV-2 variant XE and the closely related variants XD and XF.	Does not meet the inclusion criteria.
(Pawankar <i>et al.</i> , 2022)	Comparison and changes in the epidemiology, clinical profile, therapeutics and public health measures for the COVID-19 pandemic in the Asia Pacific region. Abstract mentions recent introduction of Paxlovid.	Does not meet the inclusion criteria.

Author(s)	Summary	Reason for Exclusion
(Peluso <i>et al.</i> , 2022)	Report of 4 cases from a post-COVID cohort study who received nirmatrelvir as part of clinical care and who experiences different outcomes.	Does not meet the inclusion criteria.
(Persad, Peek and Shah, 2022)	Published in late 2021, when the federal government rationed Paxlovid doses. Hence, this paper identifies relevant ethical principles and priority groups for access to Paxlovid.	Does not meet the inclusion criteria.
(Pesko <i>et al.</i> , 2022)	No abstract available on pubmed.	
(Phizackerley, 2022)	No abstract available on pubmed.	
(Priya, Basit and Bandyopadhyay, 2022)	Examine modifications of a promising peptide-based inhibitor of the spike protein, LCB3, against common mutations in the target protein. In consequence, LCB3 retains its efficacy against the spike protein.	Does not meet the inclusion criteria.
(Reina and Iglesias, 2022)	Discussing Paxlovid's efficacy after publication of clinical results. Article is in Spanish.	Does not meet the inclusion criteria.
(Ridgway <i>et al.</i> , 2022)	Discussion of a new class of sartan-like arterial antihypertensive drugs (referred to as "bisartans") as treatment for COVID-19. Abstract notes that bisartans do not inhibit SARS-CoV-2 infection in bioassays as effectively as Paxlovid.	Does not meet the inclusion criteria.
(Roberts, Duncan and Cairns, 2022)	No abstract available on pubmed.	
(S K et al., 2022)	Discussion of risk of drug interactions between treatments for COVID-19	Does not meet the inclusion criteria.

Author(s)	Summary	Reason for Exclusion
	and drugs used in treating comorbid conditions like diabetes or cardiovascular illness.	
(Wang, Gelfand and Calabrese, 2022)	Summarizes diagnostic and therapeutic management of COVID-19 for outpatients. Abstract names Paxlovid was the preferred treatment for mild cases with high risk of disease progression.	Does not meet the inclusion criteria.
(Sakamuru, Huang and Xia, 2022)	Assessing currently available COVID-19 drugs for their potential toxicological effects and mechanisms.	Does not meet the inclusion criteria.
(Salerno <i>et al.</i> , 2022)	Describes clinical experience with 25 organ transplant recipients who were prescribed Paxlovid. Their results suggest that clinically significant interaction between Paxlovid and immunosuppressive agents can be reasonably managed with a standardized dosing protocol	Does not meet the inclusion criteria.
(Sánchez Fabra and Herrero Jordán, 2022)	No abstract available on pubmed.	
(Saravolatz, Depcinski and Sharma, 2022)	Review of molnupiravir and Paxlovid with regard to their mechanisms of action, their antiviral activity, pharmacokinetics, drug interactions and clinical experience including trials, adverse events, recommended indications and formulary considerations.	Does not meet the inclusion criteria
(Sathish <i>et al.</i> , 2022)	Providing vivo safety assessments of Paxlovid by studies in rats and monkeys.	Does not meet the inclusion criteria.
(Schöning et al., 2022)	Simulation of molnupiravir	Does not meet the inclusion

Author(s)	Summary	Reason for Exclusion
	treatment to judge effectiveness of antiviral therapy in highly-transmissible variants.	criteria.
(Schwartz, 2022)	No abstract available on pubmed.	
(Secretan et al., 2022)	Discussing the intrinsic stability of Nirmatrelvir and the degrading products formed under forced conditions.	Does not meet the inclusion criteria.
(Service, 2022)	No abstract available on pubmed.	
(Setz et al., 2022)	Introduce the ability of the combination of pamapimod and pioglitazone to inhibit SARS-CoV-2 replication in vitro. Hence, this combination is a potential treatment of COVID-19 and is evaluated (at the time of writing) in a phase II clinical study.	Does not meet the inclusion criteria.
(Singh <i>et al.</i> , 2022)	Provides practical clinical guidelines for using molnupiravor in COVID-19 patients.	Does not meet the inclusion criteria.
(Stifani <i>et al.</i> , 2022)	Discussing contraceptive care in times of the Pandemic. Abstract mentions that combined hormonal contraceptive users who take Paxlovid should consider an additional contraceptive method for the duration of Paxlovid treatment.	Does not meet the inclusion criteria.
(Sun <i>et al.</i> , 2022)	No abstract available on pubmed.	
(Tang <i>et al.</i> , 2022)	Development and validation of a method to quantify almonertinib in rat plasma to study the effects of Paxlovid on the pharmacokinetics of	Does not meet the inclusion criteria.

Author(s)	Summary	Reason for Exclusion
	almonertinib in rats.	
(Tanne, 2022)	No abstract available on pubmed.	
(Tarnawski and Ahluwalia, 2022)	Presenting the role of endothelial and vascular components as major targets for COVID-19-induced tissue injury, spreading to various organs and injury healing as well as current COVID-19 treatments.	Does not meet the inclusion criteria.
(Tene <i>et al.</i> , 2022)	Israelian study to determine the number of patients who could be included in a prospective Real World Evidence Study to study Paxlovid's effect on patients' outcomes as well as assessment of comparability between patients who received the treatment and patients who did not.	
(Tolomeo, Cavalli and Cascio, 2022)	Discussing the important role of the signal transducer and activator of transcription (STAT) 1 protein in antiviral immune response and how viruses like Ebola and SARS-CoV-2 have developed the ability to inhibit this transcription factor.	Does not meet the inclusion criteria.
(Traynor, 2022)	No abstract available on pubmed.	
(Uchikoba, Yamada and Tsuzuki, 2022)	No abstract available on pubmed.	
(Usher, 2022)	No abstract available on pubmed.	
(Viedma Martínez, Gallo Pineda and Jiménez Gallo, 2022)	Review of the indications of immunosuppresants and immunomodulators and guidance on which mild to moderate COVID-19	Does not meet the inclusion criteria.

Author(s)	Summary	Reason for Exclusion
	patients might benefit from their use in dermatology.	
(Vitiello, Ferrara, <i>et al.</i> , 2022)	Review which provides an overview regarding the molecular profile of the Omicron variant, as well as its transmissibility and the remaining vaccine effectiveness. Mentioned molnupiravir and Paxlovid as oral treatments of COVID-19.	Does not meet the inclusion criteria.
(Vitiello, La Porta, <i>et al.</i> , 2022)	Written when the Omicron variant hat just emerged and molnupiravir and Paxlovid had only undergone clinical study. Briefly reviewing the impact of these two new oral antivirals.	Does not meet the inclusion criteria.
(Vuorio, Kovanen and Raal, 2022)	Discussion of drug interactions when simultaneously taking Paxlovid and cholesterol-lowering drugs.	Does not meet the inclusion criteria.
(Wu <i>et al.</i> , 2022)	Summary of the current progress in the structural biology of SARS-CoV-2 as well as presentation of structure-based design of Paxlovid, molnupiravor and VV116 to emphasize the importance of structure in drug development for COVID-19	Does not meet the inclusion criteria.
(Y. Wang et al., 2022)	No abstract available on pubmed.	
(Yan <i>et al.</i> , 2022)	Recruitment of 5 pediatric cases with underlying disease who were treated with Paxlovid as well as 30 age-matched patients with underlying disease who were not treated with Paxlovid as controls. Assessment of efficacy and safety of Paxlovid as well as	Does not meet the inclusion criteria.

Author(s)	Summary	Reason for Exclusion
	inter-group comparisons.	
(Yang <i>et al.</i> , 2022)	From evolutionary and structural standpoints possible mutations in Mpro leading to evasion of nirmatrelvir are discussed.	Does not meet the inclusion criteria.
(Young, Papiro and Greenberg, 2022)	Case report of a 14 year old female kidney transplant, whose COVID-19 infection was treated with Paxlovid.	Does not meet the inclusion criteria.
(Wang and Chan, 2022)	Cystic fibrosis patients are at increased risk for drug-drug interaction when taking Paxlovid. Here, these interactions are explored using a physiologically-based pharmacokinetic modeling approach.	Does not meet the inclusion criteria.
(Wang and Yang, 2022)	Letter to the editor discussing the potential of Paxlovid to treat COVID-19	Does not meet the inclusion criteria.
(Zhang, 2022)	Review presenting an update on fluorinated COVID-19 drugs. Here, current knowledge of these drugs' molecular design, metabolism and pharmacokinetics as well as mechanism of action, is provided.	Does not meet the inclusion criteria.
(Zhu and Ang, 2022)	Review which aims to provide a compact and updated summary of pediatric COVID-19 diagnosis and management. Abstract mentions that in patients at increased risk of progression, Paxlovid (among other treatments) should be considered.	Does not meet the inclusion criteria.

Table S3: Publications, which were taken into consideration, but which did not meet our inclusion criteria and were hence not included in the review.

References

Abdelrahim, M. *et al.* (2022) 'Thymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge', *Frontiers in pharmacology*, 13, p. 848676. Available at: https://doi.org/10.3389/fphar.2022.848676.

Alshanqeeti, S. and Bhargava, A. (2022) 'COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature', *Cureus*, 14(6), p. e26239. Available at: https://doi.org/10.7759/cureus.26239.

Alvarado, Y.J. *et al.* (2022) 'Interaction of the new inhibitor paxlovid (PF-07321332) and ivermectin with the monomer of the main protease SARS-CoV-2: A volumetric study based on molecular dynamics, elastic networks, classical thermodynamics and SPT', *Computational biology and chemistry*, 99, p. 107692. Available at: https://doi.org/10.1016/j.compbiolchem.2022.107692.

Arbel, R. *et al.* (2022) 'Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron Surge'. Available at: https://doi.org/10.21203/rs.3.rs-1705061/v1.

Ashour, N.A. *et al.* (2022) 'A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval', *Drug design, development and therapy*, 16, pp. 685–715. Available at: https://doi.org/10.2147/DDDT.S354841.

Atluri, K., Aimlin, I. and Arora, S. (2022) 'Current Effective Therapeutics in Management of COVID-19', *Journal of clinical medicine research*, 11(13). Available at: https://doi.org/10.3390/jcm11133838.

Azanza, J.R. *et al.* (2022) 'Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences', *Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia*, 35(4), pp. 357–361. Available at: https://doi.org/10.37201/req/054.2022.

Bartha, F.A. *et al.* (2022) 'In Silico Evaluation of Paxlovid's Pharmacometrics for SARS-CoV-2: A Multiscale Approach', *Viruses*, 14(5). Available at: https://doi.org/10.3390/v14051103.

Ben Hlima, H. *et al.* (2022) 'In silico evidence of antiviral activity against SARS-CoV-2 main protease of oligosaccharides from Porphyridium sp', *The Science of the total environment*, 836, p. 155580. Available at: https://doi.org/10.1016/j.scitotenv.2022.155580.

Berar Yanay, N. *et al.* (2022) 'Paxlovid-Tacrolimus Drug-Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19', *Clinical drug investigation*, 42(8), pp. 693–695. Available at: https://doi.org/10.1007/s40261-022-01180-4.

Birabaharan, M. and Martin, T.C.S. (2022) 'Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19', *The American journal of emergency medicine* [Preprint]. Available at: https://doi.org/10.1016/j.ajem.2022.08.012.

Borio, L.L., Bright, R.A. and Emanuel, E.J. (2022) 'A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics', *JAMA: the journal of the American Medical Association*, 327(3), pp. 215–216. Available at: https://doi.org/10.1001/jama.2021.24165.

Brooks, J.K., Song, J.H. and Sultan, A.S. (2022) 'Paxlovid-associated dysgeusia', *Oral diseases* [Preprint]. Available at: https://doi.org/10.1111/odi.14312.

Burki, T. (2022) 'The future of Paxlovid for COVID-19', *The Lancet. Respiratory medicine*, 10(7), p. e68. Available at: https://doi.org/10.1016/S2213-2600(22)00192-8.

Buxeraud, J., Faure, S. and Fougere, É. (2022) '[Nirmatrelvir/ritonavir (Paxlovid®), a treatment for Covid-19]', *Actualites pharmaceutiques*, 61(617), pp. 10–12. Available at: https://doi.org/10.1016/j.actpha.2022.05.002.

Callaway, E. (2022) 'COVID rebound is surprisingly common - even without Paxlovid', *Nature* [Preprint]. Available at: https://doi.org/10.1038/d41586-022-02121-z.

Catlin, N.R. *et al.* (2022) 'Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models', *Reproductive toxicology*, 108, pp. 56–61. Available at: https://doi.org/10.1016/j.reprotox.2022.01.006.

Cerón-Carrasco, J.P. (2022) 'When Virtual Screening Yields Inactive Drugs: Dealing with False Theoretical Friends', *ChemMedChem*, 17(16), p. e202200278. Available at: https://doi.org/10.1002/cmdc.202200278.

Chang, Y.-C. *et al.* (2022) 'A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant', *EMBO molecular medicine*, 14(4), p. e15298. Available at: https://doi.org/10.15252/emmm.202115298.

Chen, H.-Y., Chang, R. and Wei, J.C.C. (2022) 'Epidemiological study on the effectiveness of Paxlovid', *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* [Preprint]. Available at: https://doi.org/10.1093/cid/ciac664.

Choi, J.H. *et al.* (2022) 'Can Panax ginseng help control cytokine storm in COVID-19?', *Journal of ginseng research*, 46(3), pp. 337–347. Available at: https://doi.org/10.1016/j.jgr.2022.02.006.

Collaborative, T.O. *et al.* (2022) 'Trends, variation and clinical characteristics of recipients of antivirals and neutralising monoclonal antibodies for non-hospitalised COVID-19: a descriptive cohort study of 23.4 million people in OpenSAFELY'. Available at: https://doi.org/10.1101/2022.03.07.22272026.

Coulson, J.M. *et al.* (2022) 'COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy', *The Journal of infection*, 85(4), pp. 436–480. Available at: https://doi.org/10.1016/j.jinf.2022.06.011.

Couzin-Frankel, J. (2021) 'Antiviral pills could change pandemic's course', *Science*, 374(6569), pp. 799–800. Available at: https://doi.org/10.1126/science.acx9605.

Dai, E.Y. *et al.* (2022) 'Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir', *medRxiv*: *the preprint server for health sciences* [Preprint]. Available at: https://doi.org/10.1101/2022.08.04.22278378.

Deo, R. *et al.* (2022) 'Viral and Symptom Rebound in Untreated COVID-19 Infection', *medRxiv: the preprint server for health sciences* [Preprint]. Available at: https://doi.org/10.1101/2022.08.01.22278278.

Drożdżal, S. *et al.* (2021) 'An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment', *Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy*, 59, p. 100794. Available at: https://doi.org/10.1016/j.drup.2021.100794.

Dryden-Peterson, S. *et al.* (2022) 'Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system'. Available at: https://doi.org/10.1101/2022.06.14.22276393.

Eng, H. *et al.* (2022) 'Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans', *Drug metabolism and disposition: the biological fate of chemicals*, 50(5), pp. 576–590. Available at: https://doi.org/10.1124/dmd.121.000801.

Epling, B.P. *et al.* (2022) 'COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir', *medRxiv*: *the preprint server for health sciences* [Preprint]. Available at: https://doi.org/10.1101/2022.06.16.22276392.

Extance, A. (2022) 'Covid-19: What is the evidence for the antiviral Paxlovid?', *BMJ*, 377, p. o1037. Available at: https://doi.org/10.1136/bmj.o1037.

Feingold, K.R. (2022) 'Lipid and Lipoprotein Levels in Patients with COVID-19 Infections', in K.R. Feingold et al. (eds) *Endotext*. South Dartmouth (MA): MDText.com, Inc. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33237691.

Feng, Y. *et al.* (2022) 'Real-world effectiveness of Yindan Jiedu granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study', *Frontiers in pharmacology*, 13, p. 978979. Available at: https://doi.org/10.3389/fphar.2022.978979.

Fernando, K. *et al.* (2022) 'Achieving end-to-end success in the clinic: Pfizer's learnings on R&D productivity', *Drug discovery today*, 27(3), pp. 697–704. Available at: https://doi.org/10.1016/j.drudis.2021.12.010.

Ferrara, F. *et al.* (2022) 'Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view', *Inflammopharmacology*, 30(5), pp. 1927–1931. Available at: https://doi.org/10.1007/s10787-022-01055-2.

Fishbane, S., Hirsch, J.S. and Nair, V. (2022) 'Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection', *American journal of kidney diseases: the official journal of the National Kidney Foundation*, 79(4), pp. 480–482. Available at: https://doi.org/10.1053/j.ajkd.2022.01.001.

Ganatra, S. *et al.* (2022) 'Oral Nirmatrelvir and Ritonavir in Non-hospitalized Vaccinated Patients with Covid-19', *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* [Preprint]. Available at: https://doi.org/10.1093/cid/ciac673.

Gandhi, R.T., Malani, P.N. and Del Rio, C. (2022) 'COVID-19 Therapeutics for Nonhospitalized Patients', *JAMA: the journal of the American Medical Association*, 327(7), pp. 617–618. Available at: https://doi.org/10.1001/jama.2022.0335.

García-Lledó, A. *et al.* (2022) 'Pharmacological treatment of COVID-19: an opinion paper', *Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia*, 35(2), pp. 115–130. Available at: https://doi.org/10.37201/reg/158.2021.

Gold, J.A.W. *et al.* (2022) 'Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code-Level Social Vulnerability - United States, December 23, 2021-May 21, 2022', *MMWR. Morbidity and mortality weekly report*, 71(25), pp. 825–829. Available at: https://doi.org/10.15585/mmwr.mm7125e1.

Greasley, S.E. et al. (2022) 'Structural basis for the in vitro efficacy of nirmatrelvir against

- SARS-CoV-2 variants', *The Journal of biological chemistry*, 298(6), p. 101972. Available at: https://doi.org/10.1016/j.jbc.2022.101972.
- Halford, B. (2022) 'The Path to Paxlovid', *ACS central science*, 8(4), pp. 405–407. Available at: https://doi.org/10.1021/acscentsci.2c00369.
- Hammond, J. *et al.* (2022) 'Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19', *The New England journal of medicine*, 386(15), pp. 1397–1408. Available at: https://doi.org/10.1056/NEJMoa2118542.
- Hong, E. *et al.* (2022) 'Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19', *Clinical pharmacology and therapeutics*, 111(6), pp. 1324–1333. Available at: https://doi.org/10.1002/cpt.2585.
- Ho, W.S. *et al.* (2022) 'COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?', *Pharmacological research: the official journal of the Italian Pharmacological Society*, 179, p. 106201. Available at: https://doi.org/10.1016/j.phrs.2022.106201.
- Huang, J. *et al.* (2022) 'Case report: Application of nirmatrelvir/ritonavir to treat COVID-19 in a severe aplastic anemia child after allogeneic hematopoietic stem cell transplantation', *Frontiers in pediatrics*, 10, p. 935118. Available at: https://doi.org/10.3389/fped.2022.935118.
- Hung, Y.-P. *et al.* (2022) 'Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?', *Antibiotics (Basel, Switzerland)*, 11(2). Available at: https://doi.org/10.3390/antibiotics11020220.
- Islam, T. *et al.* (2022) 'Comparative evaluation of authorized drugs for treating Covid-19 patients', *Health science reports*, 5(4), p. e671. Available at: https://doi.org/10.1002/hsr2.671.
- Javaux, C. and Ader, F. (2022) '[Prise en charge médicale du Covid-19, hors réanimation]', *La Revue du praticien*, 72(5), pp. 505–510. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35899636.
- Joyce, R.P., Hu, V.W. and Wang, J. (2022) 'The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations', *Medicinal chemistry research: an international journal for rapid communications on design and mechanisms of action of biologically active agents*, 31(10), pp. 1637–1646. Available at: https://doi.org/10.1007/s00044-022-02951-6.
- Katella, K. (2022) *13 Things To Know About Paxlovid, the Latest COVID-19 Pill, yalemedicine.org.* Available at: https://www.yalemedicine.org/news/13-things-to-know-paxlovid-covid-19 (Accessed: 4 August 2022).
- Kozlov, M. (2022) 'Why scientists are racing to develop more COVID antivirals', *Nature*, 601(7894), p. 496. Available at: https://doi.org/10.1038/d41586-022-00112-8.
- Kuehn, B.M. (2022) 'Rehospitalization, Emergency Visits After Paxlovid Treatment Are Rare', *JAMA: the journal of the American Medical Association*, 328(4), p. 323. Available at: https://doi.org/10.1001/jama.2022.11942.
- Lamb, Y.N. (2022) 'Nirmatrelvir Plus Ritonavir: First Approval', *Drugs*, 82(5), pp. 585–591.

- Available at: https://doi.org/10.1007/s40265-022-01692-5.
- Ledford, H. (2022) 'Hundreds of COVID trials could provide a deluge of new drugs', *Nature*, 603(7899), pp. 25–27. Available at: https://doi.org/10.1038/d41586-022-00562-0.
- Ledford, H. and Maxmen, A. (2022) 'African clinical trial denied access to key COVID drug Paxlovid', *Nature*, pp. 412–413. Available at: https://doi.org/10.1038/d41586-022-00919-5.
- Lee, J.T. *et al.* (2022) 'Genetic Surveillance of SARS-CoV-2 Mpro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid', *mBio*, 13(4), p. e0086922. Available at: https://doi.org/10.1128/mbio.00869-22.
- Lemaitre, F., Grégoire, M., *et al.* (2022) 'Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)', *Therapie* [Preprint]. Available at: https://doi.org/10.1016/j.therap.2022.03.005.
- Lemaitre, F., Budde, K., *et al.* (2022) 'Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir/ritonavir in patients with COVID-19', *Therapeutic drug monitoring* [Preprint]. Available at: https://doi.org/10.1097/FTD.000000000001014.
- Lieber, C.M. and Plemper, R.K. (2022) '4'-Fluorouridine Is a Broad-Spectrum Orally Available First-Line Antiviral That May Improve Pandemic Preparedness', *DNA and cell biology*, 41(8), pp. 699–704. Available at: https://doi.org/10.1089/dna.2022.0312.
- Li, P. *et al.* (2022) 'SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination', *Cell research*, 32(3), pp. 322–324. Available at: https://doi.org/10.1038/s41422-022-00618-w.
- Liu, C. *et al.* (2022) 'Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19', *Frontiers in nutrition*, 9, p. 927092. Available at: https://doi.org/10.3389/fnut.2022.927092.
- Liu, C. *et al.* (2022) 'Simultaneous determination of nirmatrelvir and ritonavir in human plasma using LC-MS/MS and its pharmacokinetic application in healthy Chinese volunteers', *Biomedical chromatography: BMC*, p. e5456. Available at: https://doi.org/10.1002/bmc.5456.
- Logue, J. *et al.* (2022) 'PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19', *Communications biology*, 5(1), p. 808. Available at: https://doi.org/10.1038/s42003-022-03766-2.
- Lu, G. *et al.* (2022) 'Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave', *Emerging microbes & infections*, 11(1), pp. 2045–2054. Available at: https://doi.org/10.1080/22221751.2022.2109517.
- Mahaboob Ali, A.A. *et al.* (2022) 'Ayurvedic formulations: Potential COVID-19 therapeutics?', *Phytomedicine Plus : International journal of phytotherapy and phytopharmacology*, 2(3), p. 100286. Available at: https://doi.org/10.1016/j.phyplu.2022.100286.
- Mahase, E. (2021) 'Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports', *BMJ*, 375, p. n2713. Available at: https://doi.org/10.1136/bmj.n2713.
- Malden, D.E. et al. (2022) 'Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment California, December 2021-May 2022', MMWR.

Morbidity and mortality weekly report, 71(25), pp. 830–833. Available at: https://doi.org/10.15585/mmwr.mm7125e2.

Manus, J.-M. (2022) 'Pfizer, résultats très prometteurs de l'antiviral oral paxlovid', *Revue francophone des laboratoires : RFL*, 2022(541), p. 5. Available at: https://doi.org/10.1016/S1773-035X(22)00106-X.

Marzi, M. et al. (2022) 'Paxlovid: Mechanism of Action, Synthesis, and In Silico Study', BioMed research international, 2022, p. 7341493. Available at: https://doi.org/10.1155/2022/7341493.

Marzolini, C. *et al.* (2022) 'Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications', *Clinical pharmacology and therapeutics* [Preprint]. Available at: https://doi.org/10.1002/cpt.2646.

McDonald, E.G. and Lee, T.C. (2022a) 'Association nirmatrelvir/ritonavir contre la COVID-19', *CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne*, 194(9), pp. E365–E366. Available at: https://doi.org/10.1503/cmaj.220081-f.

McDonald, E.G. and Lee, T.C. (2022b) 'Nirmatrelvir-ritonavir for COVID-19', *CMAJ:* Canadian Medical Association journal = journal de l'Association medicale canadienne, 194(6), p. E218. Available at: https://doi.org/10.1503/cmaj.220081.

McMillan, N.A.J., Morris, K.V. and Idris, A. (2022) 'RNAi to treat SARS-CoV-2-variant proofing the next generation of therapies', *EMBO molecular medicine*, 14(4), p. e15811. Available at: https://doi.org/10.15252/emmm.202215811.

Mikus, G. et al. (2022) 'Oral Drugs Against COVID-19', Deutsches Arzteblatt international, 119(15), pp. 263–269. Available at: https://doi.org/10.3238/arztebl.m2022.0152.

Moghadasi, S.A. *et al.* (2022) 'Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors', *bioRxiv*: *the preprint server for biology* [Preprint]. Available at: https://doi.org/10.1101/2022.08.07.503099.

Mohapatra, R.K. *et al.* (2022) 'Omicron (B.1.1.529) variant of SARS-CoV-2: Concerns, challenges, and recent updates', *Journal of medical virology*, 94(6), pp. 2336–2342. Available at: https://doi.org/10.1002/jmv.27633.

Mótyán, J.A. *et al.* (2022) 'Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease', *International journal of molecular sciences*, 23(7). Available at: https://doi.org/10.3390/ijms23073507.

Najjar-Debbiny, R. *et al.* (2022) 'Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients', *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* [Preprint]. Available at: https://doi.org/10.1093/cid/ciac443.

Ng, T.I. *et al.* (2022) 'Antiviral Drug Discovery for the Treatment of COVID-19 Infections', *Viruses*, 14(5). Available at: https://doi.org/10.3390/v14050961.

Nocentini, A., Capasso, C. and Supuran, C.T. (2022) 'Perspectives on the design and discovery of α -ketoamide inhibitors for the treatment of novel coronavirus: where do we stand and where do we go?', *Expert opinion on drug discovery*, 17(6), pp. 547–557. Available at: https://doi.org/10.1080/17460441.2022.2052847.

- de Oliveira, V. *et al.* (2022) 'H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS-CoV-2 main protease through a nonnative hydrogen bond', *Research square* [Preprint]. Available at: https://doi.org/10.21203/rs.3.rs-1915291/v1.
- Ou, J. *et al.* (2022) 'A yeast-based system to study SARS-CoV-2 M pro structure and to identify nirmatrelvir resistant mutations', *bioRxiv*: *the preprint server for biology* [Preprint]. Available at: https://doi.org/10.1101/2022.08.06.503039.
- Ouyang, J. *et al.* (2022) 'SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders', *Frontiers in public health*, 10, p. 945448. Available at: https://doi.org/10.3389/fpubh.2022.945448.
- Parums, D.V. (2022) 'Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients', *Medical science monitor: international medical journal of experimental and clinical research*, 28, p. e935952. Available at: https://doi.org/10.12659/MSM.935952.
- Pavan, M. *et al.* (2022a) 'Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)?', *Journal of enzyme inhibition and medicinal chemistry*, 37(1), pp. 1077–1082. Available at: https://doi.org/10.1080/14756366.2022.2062336.
- Pavan, M. *et al.* (2022b) 'From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?', *Journal of enzyme inhibition and medicinal chemistry*, 37(1), pp. 1704–1714. Available at: https://doi.org/10.1080/14756366.2022.2081847.
- Pawankar, R. *et al.* (2022) 'Asia Pacific perspectives on the second year of the COVID-19 pandemic: A follow-up survey', *Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology*, 52(8), pp. 965–973. Available at: https://doi.org/10.1111/cea.14191.
- Peluso, M.J. *et al.* (2022) 'Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies', *Pathogens & immunity*, 7(1), pp. 95–103. Available at: https://doi.org/10.20411/pai.v7i1.518.
- Persad, G., Peek, M.E. and Shah, S.K. (2022) 'Fair Allocation of Scarce Therapies for Coronavirus Disease 2019 (COVID-19)', *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, 75(1), pp. e529–e533. Available at: https://doi.org/10.1093/cid/ciab1039.
- Pesko, B. *et al.* (2022) 'Safety, and Tolerability of Paxlovid (nirmatrelvir/ritonavir) in High Risk Patients', *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* [Preprint]. Available at: https://doi.org/10.1093/cid/ciac588.
- Phizackerley, D. (2022) 'Three more points about Paxlovid for covid-19', *BMJ*, 377, p. o1397. Available at: https://doi.org/10.1136/bmj.o1397.
- Prikis, M. and Cameron, A. (2022) 'Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report', *Transplantation proceedings* [Preprint]. Available at: https://doi.org/10.1016/j.transproceed.2022.04.015.
- Priya, P., Basit, A. and Bandyopadhyay, P. (2022) 'A strategy to optimize the peptide-based inhibitors against different mutants of the spike protein of SARS-CoV-2', *Journal of biomolecular structure & dynamics*, pp. 1–12. Available at:

https://doi.org/10.1080/07391102.2022.2103587.

Reina, J. and Iglesias, C. (2022) '[Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination]', *Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia*, 35(3), pp. 236–240. Available at: https://doi.org/10.37201/req/002.2022.

Ridgway, H. *et al.* (2022) 'Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2', *Computational and structural biotechnology journal*, 20, pp. 2091–2111. Available at: https://doi.org/10.1016/j.csbj.2022.04.010.

Roberts, J.A., Duncan, A. and Cairns, K.A. (2022) 'Pandora's box: Paxlovid, prescribing, pharmacists and pandemic', *American journal of pharmacogenomics: genomics-related research in drug development and clinical practice*, 52(1), pp. 1–4. Available at: https://doi.org/10.1002/jppr.1799.

Rubin, E.J., Baden, L.R. and Morrissey, S. (2022) 'Audio Interview: A New Antiviral against Covid-19', *The New England journal of medicine*, 386(7), p. e25. Available at: https://doi.org/10.1056/NEJMe2202349.

Rubin, R. (2022) 'From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid', *JAMA: the journal of the American Medical Association*, 327(24), pp. 2380–2382. Available at: https://doi.org/10.1001/jama.2022.9925.

Sakamuru, S., Huang, R. and Xia, M. (2022) 'Use of Tox21 Screening Data to Evaluate the COVID-19 Drug Candidates for Their Potential Toxic Effects and Related Pathways', *Frontiers in pharmacology*, 13, p. 935399. Available at: https://doi.org/10.3389/fphar.2022.935399.

Salerno, D.M. *et al.* (2022) 'Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients', *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 22(8), pp. 2083–2088. Available at: https://doi.org/10.1111/ajt.17027.*

Sánchez Fabra, D. and Herrero Jordán, T. (2022) 'Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns', *Enfermedades infecciosas y microbiologia clinica* [Preprint]. Available at: https://doi.org/10.1016/j.eimc.2022.04.007.

Saravolatz, L.D., Depcinski, S. and Sharma, M. (2022) 'Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs', *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* [Preprint]. Available at: https://doi.org/10.1093/cid/ciac180.

Sathish, J.G. *et al.* (2022) 'Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid[™]', *International journal of toxicology*, 41(4), pp. 276–290. Available at: https://doi.org/10.1177/10915818221095489.

Schöning, V. *et al.* (2022) 'Effectiveness of Antiviral Therapy in Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation Study', *Frontiers in pharmacology*, 13, p. 816429. Available at: https://doi.org/10.3389/fphar.2022.816429.

Schwartz, E. (2022) 'Does ivermectin have a place in the treatment of mild Covid-19?', New

- *microbes and new infections*, 46, p. 100985. Available at: https://doi.org/10.1016/j.nmni.2022.100985.
- Secretan, P.-H. *et al.* (2022) 'Unequal Behaviour between Hydrolysable Functions of Nirmatrelvir under Stress Conditions: Structural and Theoretical Approaches in Support of Preformulation Studies', *Pharmaceutics*, 14(8). Available at: https://doi.org/10.3390/pharmaceutics14081720.
- Service, R.F. (2022) 'Bad news for Paxlovid? Resistance may be coming', *Science*, 377(6602), pp. 138–139. Available at: https://doi.org/10.1126/science.add8037.
- Setz, C. *et al.* (2022) 'Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern', *International journal of molecular sciences*, 23(12). Available at: https://doi.org/10.3390/ijms23126830.
- Singh, A.K. *et al.* (2022) 'An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19', *Diabetes & metabolic syndrome*, 16(2), p. 102396. Available at: https://doi.org/10.1016/j.dsx.2022.102396.
- S K, S.R. *et al.* (2022) 'Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases', *Diabetes & metabolic syndrome*, 16(3), p. 102451. Available at: https://doi.org/10.1016/j.dsx.2022.102451.
- Stifani, B.M. *et al.* (2022) 'Society of Family Planning Clinical Recommendations: Contraceptive Care in the Context of Pandemic Response', *Contraception*, 113, pp. 1–12. Available at: https://doi.org/10.1016/j.contraception.2022.05.006.
- Sun, F. *et al.* (2022) 'Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection', *The Lancet infectious diseases* [Preprint]. Available at: https://doi.org/10.1016/S1473-3099(22)00430-3.
- Tang, P.-F. *et al.* (2022) 'Development and Validation of a UHPLC-MS/MS Method for Quantitation of Almonertinib in Rat Plasma: Application to an in vivo Interaction Study Between Paxlovid and Almonertinib', *Frontiers in pharmacology*, 13, p. 960311. Available at: https://doi.org/10.3389/fphar.2022.960311.
- Tanne, J.H. (2022) 'Covid-19: FDA authorises pharmacists to prescribe Paxlovid', *BMJ*, 378, p. o1695. Available at: https://doi.org/10.1136/bmj.o1695.
- Tarnawski, A.S. and Ahluwalia, A. (2022) 'Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs', *World journal of gastroenterology: WJG*, 28(3), pp. 275–289. Available at: https://doi.org/10.3748/wjg.v28.i3.275.
- Tene, L. *et al.* (2022) 'Describing COVID-19 Patients During The First Two Months of Paxlovid (nirmatrelvir/ritonavir) Initiation in a Large HMO in Israel', *bioRxiv*. Available at: https://doi.org/10.1101/2022.05.02.22274586.
- Tolomeo, M., Cavalli, A. and Cascio, A. (2022) 'STAT1 and Its Crucial Role in the Control of Viral Infections', *International journal of molecular sciences*, 23(8). Available at: https://doi.org/10.3390/ijms23084095.
- Traynor, K. (2022) 'Québec authorizes pharmacists to prescribe Paxlovid', American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System

Pharmacists [Preprint]. Available at: https://doi.org/10.1093/ajhp/zxac163.

Uchikoba, S., Yamada, G. and Tsuzuki, S. (2022) 'Methodological concerns regarding a retrospective study with real-world data on Paxlovid® in Israel', *Clinical infectious diseases:* an official publication of the Infectious Diseases Society of America [Preprint]. Available at: https://doi.org/10.1093/cid/ciac665.

Usher, A.D. (2022) 'The global COVID-19 treatment divide', *The Lancet*, 399(10327), pp. 779–782. Available at: https://doi.org/10.1016/S0140-6736(22)00372-5.

Vangeel, L. *et al.* (2022) 'Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern', *Antiviral research*, 198, p. 105252. Available at: https://doi.org/10.1016/j.antiviral.2022.105252.

Viedma Martínez, M., Gallo Pineda, G. and Jiménez Gallo, D. (2022) 'Practical Guide to New Treatments for SARS-CoV-2 Infection in Dermatology Patients Being Treated With Common Immunomodulators', *Actas dermo-sifiliograficas* [Preprint]. Available at: https://doi.org/10.1016/j.ad.2022.07.020.

Vitiello, A., Ferrara, F., *et al.* (2022) 'Advances in the Omicron variant development', *Journal of internal medicine*, 292(1), pp. 81–90. Available at: https://doi.org/10.1111/joim.13478.

Vitiello, A., La Porta, R., *et al.* (2022) 'Pandemic COVID-19, an update of current status and new therapeutic strategies', *Naunyn-Schmiedeberg's archives of pharmacology*, 395(10), pp. 1159–1165. Available at: https://doi.org/10.1007/s00210-022-02265-9.

Vuorio, A., Kovanen, P.T. and Raal, F. (2022) 'Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid[™] therapy', *Future virology* [Preprint]. Available at: https://doi.org/10.2217/fvl-2022-0060.

Wang, L., Berger, N.A., et al. (2022) 'COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022', medRxiv: the preprint server for health sciences [Preprint]. Available at: https://doi.org/10.1101/2022.06.21.22276724.

Wang, L., Volkow, N.D., *et al.* (2022) 'COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period'. Available at: https://doi.org/10.1101/2022.08.04.22278450.

Wang, S., Gelfand, J.M. and Calabrese, C. (2022) 'Outpatient Management of COVID-19: A Primer for the Dermatologist', *Current dermatology reports*, pp. 1–10. Available at: https://doi.org/10.1007/s13671-022-00368-3.

Wang, Y. *et al.* (2022) 'Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid', *The Journal of infection* [Preprint]. Available at: https://doi.org/10.1016/j.jinf.2022.08.012.

Wang, Z. and Chan, E.C.Y. (2022) 'Physiologically-Based Pharmacokinetic Modeling-Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 Treatment', *Clinical pharmacology and therapeutics*, 112(4), pp. 803–807. Available at: https://doi.org/10.1002/cpt.2687.

Wang, Z. and Yang, L. (2022) 'In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery', *Journal of medical virology*, 94(5), pp. 1766–1767. Available at: https://doi.org/10.1002/jmv.27540.

Wen, W. et al. (2022) 'Efficacy and safety of three new oral antiviral treatment (molnupiravir,

- fluvoxamine and Paxlovid) for COVID-19: a meta-analysis', *Annals of medicine*, 54(1), pp. 516–523. Available at: https://doi.org/10.1080/07853890.2022.2034936.
- Wong, C.K.H. *et al.* (2022) 'Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among hospitalized, non-oxygen-dependent COVID-19 patients on admission during Hong Kong's Omicron BA.2 wave: an observational study'. Available at: https://doi.org/10.1101/2022.05.19.22275291.
- Wu, C.-R. *et al.* (2022) 'Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19', *Acta pharmacologica Sinica* [Preprint]. Available at: https://doi.org/10.1038/s41401-021-00851-w.
- Yan, G. *et al.* (2022) 'The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6-14 years: a cohort study', *Annals of translational medicine*, 10(11), p. 619. Available at: https://doi.org/10.21037/atm-22-2791.
- Yang, K.S. *et al.* (2022) 'Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir', *Journal of medicinal chemistry*, 65(13), pp. 8686–8698. Available at: https://doi.org/10.1021/acs.jmedchem.2c00404.
- Young, C., Papiro, T. and Greenberg, J.H. (2022) 'Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant', *Pediatric nephrology* [Preprint]. Available at: https://doi.org/10.1007/s00467-022-05712-0.
- Zhang, C. (2022) 'Fluorine in Medicinal Chemistry: In Perspective to COVID-19', ACS omega, 7(22), pp. 18206–18212. Available at: https://doi.org/10.1021/acsomega.2c01121.
- Zhu, F. and Ang, J.Y. (2022) 'COVID-19 Infection in Children: Diagnosis and Management', *Current infectious disease reports*, 24(4), pp. 51–62. Available at: https://doi.org/10.1007/s11908-022-00779-0.